(Q34238267)

31 July 2017

Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis (English)

1 reference

31 July 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

Paul L McCormack

1

1 reference

31 July 2017

1 December 2011

1 reference

31 July 2017

1 reference

31 July 2017

71

1 reference

31 July 2017

18

1 reference

31 July 2017

2457-2489

1 reference

https://scigraph.springernature.com/pub.10.2165/11208240-000000000-00000

31 July 2017

0 references

cites work

Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials

1 reference

12 December 2020

Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?

1 reference

12 December 2020

Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies

1 reference

12 December 2020

Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib

1 reference

12 December 2020

Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study

1 reference

12 December 2020

An economic model of long-term use of celecoxib in patients with osteoarthritis

1 reference

12 December 2020

Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain

1 reference

12 December 2020

Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies

1 reference

12 December 2020

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

12 December 2020

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

1 reference

12 December 2020

The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor

1 reference

12 December 2020

A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis

1 reference

12 December 2020

Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs

1 reference

12 December 2020

Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis

1 reference

12 December 2020

Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT

1 reference

12 December 2020

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

1 reference

12 December 2020

Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis

1 reference

12 December 2020

Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials

1 reference

12 December 2020

Patient perception of the burden of weight gain and blood pressure increase among RA patients using celecoxib, rofecoxib, and non-specific NSAIDs

1 reference

12 December 2020

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

12 December 2020

Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective

1 reference

12 December 2020

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

1 reference

12 December 2020

Comparing the efficacy of cyclooxygenase 2–specific inhibitors in treating osteoarthritis: Appropriate trial design considerations and results of a randomized, placebo‐controlled trial

1 reference

12 December 2020

Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs

1 reference

12 December 2020

Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.

1 reference

12 December 2020

Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study

1 reference

12 December 2020

EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)

1 reference

12 December 2020

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

1 reference

12 December 2020

Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.

1 reference

12 December 2020

Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis

1 reference

12 December 2020

Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

1 reference

12 December 2020

Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial

1 reference

12 December 2020

Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs

1 reference

12 December 2020

New diagnosis of hypertension among celecoxib and nonselective NSAID users: a population-based cohort study

1 reference

12 December 2020

Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors

1 reference

12 December 2020

Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa.

1 reference

12 December 2020

Impact of Celecoxib restrictions in medicare beneficiaries with arthritis

1 reference

12 December 2020

Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway

1 reference

12 December 2020

Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study

1 reference

12 December 2020

Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip

1 reference

12 December 2020

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients

1 reference

12 December 2020

Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib.

1 reference

12 December 2020

Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac

1 reference

12 December 2020

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

1 reference

12 December 2020

Celecoxib 200 mg q.d. is efficacious in the management of osteoarthritis of the knee or hip regardless of the time of dosing

1 reference

12 December 2020

Celecoxib for the prevention of colorectal adenomatous polyps

1 reference

12 December 2020

Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.

1 reference

12 December 2020

Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications

1 reference

12 December 2020

Efficacy and safety of diclofenac-cholestyramine and celecoxib in osteoarthritis

1 reference

12 December 2020

Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis

1 reference

12 December 2020

Mechanism of action of aspirin-like drugs

1 reference

12 December 2020

Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies

1 reference

12 December 2020

Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis.

1 reference

12 December 2020

Safety and efficacy of oral nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis : a six-month randomised study

1 reference

12 December 2020

Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.

1 reference

12 December 2020

Overview of the arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib

1 reference

12 December 2020

Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas

1 reference

12 December 2020

Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population

1 reference

12 December 2020

Safety of celecoxib in patients with cutaneous reactions due to ASA-NSAIDs intolerance

1 reference

12 December 2020

Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease

1 reference

12 December 2020

Celecoxib for the prevention of sporadic colorectal adenomas

1 reference

12 December 2020

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

1 reference

12 December 2020

Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial

1 reference

12 December 2020

Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs

1 reference

12 December 2020

Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations

1 reference

12 December 2020

Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial

1 reference

12 December 2020

Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trial

1 reference

12 December 2020

Cardiorenal Effects of Newer NSAIDs (Celecoxib) versus Classic NSAIDs (Ibuprofen) in Patients with Arthritis

1 reference

12 December 2020

Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

1 reference

12 December 2020

Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial.

1 reference

12 December 2020

Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.

1 reference

12 December 2020

Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial

1 reference

12 December 2020

Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor

1 reference

12 December 2020

EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

1 reference

12 December 2020

Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension

1 reference

12 December 2020

Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor

1 reference

12 December 2020

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

1 reference

12 December 2020

Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects.

1 reference

12 December 2020

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

1 reference

12 December 2020

Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial

1 reference

12 December 2020

COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled, randomized, double-blind study

1 reference

12 December 2020

American pain society pain questionnaire and other pain measures in the assessment of osteoarthritis pain: a pooled analysis of three celecoxib pivotal studies

1 reference

12 December 2020

Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: A class effect?

1 reference

12 December 2020

Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen

1 reference

12 December 2020

Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland

1 reference

12 December 2020

The safety of celecoxib in patients with aspirin-sensitive asthma

1 reference

12 December 2020

Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers

1 reference

12 December 2020

Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study

1 reference

12 December 2020

The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis

1 reference

12 December 2020

First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].

1 reference

12 December 2020

Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs

1 reference

12 December 2020

Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry

1 reference

12 December 2020

Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.

1 reference

12 December 2020

The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials.

1 reference

12 December 2020

Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis

1 reference

12 December 2020

Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.

1 reference

12 December 2020

Coxibs and heart disease: what we have learned and what else we need to know

1 reference

12 December 2020

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

1 reference

12 December 2020

Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis

1 reference

12 December 2020

Celecoxib: a review of its use in the management of arthritis and acute pain

1 reference

12 December 2020

Celecoxib versus diclofenac in the management of osteoarthritis of the knee

1 reference

12 December 2020

Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis

1 reference

12 December 2020

Relationship between COX-2 specific inhibitors and hypertension

1 reference

12 December 2020

Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction

1 reference

12 December 2020

A Randomised, Double-Blind, Clinical Trial Comparing the Efficacy of Nimesulide, Celecoxib and Rofecoxib in Osteoarthritis of the Knee

1 reference

12 December 2020

Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib

1 reference

12 December 2020

Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers

1 reference

12 December 2020

Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies

1 reference

12 December 2020

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial

1 reference

12 December 2020

Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug

1 reference

12 December 2020

Functional status and health-related quality of life of elderly osteoarthritic patients treated with celecoxib

1 reference

12 December 2020

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

1 reference

12 December 2020

Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib

1 reference

12 December 2020

Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?

1 reference

12 December 2020

Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema

1 reference

12 December 2020

Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis

1 reference

12 December 2020

Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure

1 reference

12 December 2020

Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip.

1 reference

12 December 2020

Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee

1 reference

12 December 2020

Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo

1 reference

12 December 2020

Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial

1 reference

12 December 2020

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis

1 reference

12 December 2020

Tolerance to celecoxib in patients with a history of adverse reactions to nonsteroidal anti-inflammatory drugs

1 reference

12 December 2020

Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs

1 reference

12 December 2020

Safety of celecoxib in individuals allergic to sulfonamide: a pilot study

1 reference

12 December 2020

Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis

1 reference

12 December 2020

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

12 December 2020

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus

1 reference

12 December 2020

Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.

1 reference

12 December 2020

A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip.

1 reference

12 December 2020

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

12 December 2020

Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy

1 reference

12 December 2020

Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies

1 reference

12 December 2020

The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis

1 reference

12 December 2020

Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.

1 reference

12 December 2020

Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib

1 reference

12 December 2020

10.2165/11208240-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

22141388

Dimensions Publication ID

31 July 2017

0 references

1 reference

PubMed ID

22141388